vs
Cytek Biosciences, Inc.（CTKB）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是Cytek Biosciences, Inc.的1.1倍（$71.1M vs $62.1M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -70.9%，领先73.0%），Cytek Biosciences, Inc.同比增速更快（8.1% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-1.8M），过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs -4.7%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
CTKB vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.1倍
$62.1M
营收增速更快
CTKB
高出10.0%
-1.8%
净利率更高
RMAX
高出73.0%
-70.9%
自由现金流更多
RMAX
多$35.3M
$-1.8M
两年增速更快
CTKB
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $71.1M |
| 净利润 | $-44.1M | $1.4M |
| 毛利率 | 52.9% | — |
| 营业利润率 | -9.0% | 13.1% |
| 净利率 | -70.9% | 2.0% |
| 营收同比 | 8.1% | -1.8% |
| 净利润同比 | -557.1% | -75.2% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBRMAX
| Q4 25 | $62.1M | $71.1M | ||
| Q3 25 | $52.3M | $73.2M | ||
| Q2 25 | $45.6M | $72.8M | ||
| Q1 25 | $41.5M | $74.5M | ||
| Q4 24 | $57.5M | $72.5M | ||
| Q3 24 | $51.5M | $78.5M | ||
| Q2 24 | $46.6M | $78.5M | ||
| Q1 24 | $44.9M | $78.3M |
净利润CTKBRMAX
| Q4 25 | $-44.1M | $1.4M | ||
| Q3 25 | $-5.5M | $4.0M | ||
| Q2 25 | $-5.6M | $4.7M | ||
| Q1 25 | $-11.4M | $-2.0M | ||
| Q4 24 | $9.6M | $5.8M | ||
| Q3 24 | $941.0K | $966.0K | ||
| Q2 24 | $-10.4M | $3.7M | ||
| Q1 24 | $-6.2M | $-3.4M |
毛利率CTKBRMAX
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
营业利润率CTKBRMAX
| Q4 25 | -9.0% | 13.1% | ||
| Q3 25 | -17.6% | 25.0% | ||
| Q2 25 | -23.3% | 19.3% | ||
| Q1 25 | -36.1% | 7.2% | ||
| Q4 24 | 5.2% | 5.9% | ||
| Q3 24 | -8.2% | 19.4% | ||
| Q2 24 | -18.3% | 20.6% | ||
| Q1 24 | -23.9% | 5.8% |
净利率CTKBRMAX
| Q4 25 | -70.9% | 2.0% | ||
| Q3 25 | -10.5% | 5.4% | ||
| Q2 25 | -12.2% | 6.4% | ||
| Q1 25 | -27.5% | -2.6% | ||
| Q4 24 | 16.8% | 8.0% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | -22.4% | 4.7% | ||
| Q1 24 | -13.8% | -4.3% |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $341.7M | $452.4M |
| 总资产 | $461.5M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资CTKBRMAX
| Q4 25 | $90.9M | $118.7M | ||
| Q3 25 | $93.3M | $107.5M | ||
| Q2 25 | $75.5M | $94.3M | ||
| Q1 25 | $95.3M | $89.1M | ||
| Q4 24 | $98.7M | $96.6M | ||
| Q3 24 | $162.3M | $83.8M | ||
| Q2 24 | $177.9M | $66.1M | ||
| Q1 24 | $168.8M | $82.1M |
总债务CTKBRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益CTKBRMAX
| Q4 25 | $341.7M | $452.4M | ||
| Q3 25 | $378.6M | $448.1M | ||
| Q2 25 | $377.6M | $442.4M | ||
| Q1 25 | $379.6M | $433.5M | ||
| Q4 24 | $395.7M | $429.5M | ||
| Q3 24 | $385.5M | $423.1M | ||
| Q2 24 | $389.1M | $418.4M | ||
| Q1 24 | $392.6M | $412.0M |
总资产CTKBRMAX
| Q4 25 | $461.5M | $582.5M | ||
| Q3 25 | $494.9M | $582.2M | ||
| Q2 25 | $493.3M | $574.8M | ||
| Q1 25 | $482.6M | $571.4M | ||
| Q4 24 | $499.5M | $581.6M | ||
| Q3 24 | $491.2M | $578.6M | ||
| Q2 24 | $483.7M | $571.4M | ||
| Q1 24 | $492.1M | $566.7M |
负债/权益比CTKBRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $33.5M |
| 自由现金流率自由现金流/营收 | -2.9% | 47.1% |
| 资本支出强度资本支出/营收 | 1.6% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $56.8M |
8季度趋势，按日历期对齐
经营现金流CTKBRMAX
| Q4 25 | $-771.0K | $40.9M | ||
| Q3 25 | $-3.9M | $17.7M | ||
| Q2 25 | $108.0K | $4.6M | ||
| Q1 25 | $-125.0K | $5.7M | ||
| Q4 24 | $2.0M | $59.7M | ||
| Q3 24 | $13.2M | $17.6M | ||
| Q2 24 | $6.2M | $15.9M | ||
| Q1 24 | $4.0M | $9.4M |
自由现金流CTKBRMAX
| Q4 25 | $-1.8M | $33.5M | ||
| Q3 25 | $-4.6M | $16.4M | ||
| Q2 25 | $-1.5M | $2.9M | ||
| Q1 25 | $-974.0K | $4.0M | ||
| Q4 24 | $1.1M | $53.0M | ||
| Q3 24 | $12.2M | $16.3M | ||
| Q2 24 | $5.2M | $14.0M | ||
| Q1 24 | $3.4M | $6.8M |
自由现金流率CTKBRMAX
| Q4 25 | -2.9% | 47.1% | ||
| Q3 25 | -8.7% | 22.4% | ||
| Q2 25 | -3.2% | 4.0% | ||
| Q1 25 | -2.3% | 5.3% | ||
| Q4 24 | 1.9% | 73.2% | ||
| Q3 24 | 23.7% | 20.8% | ||
| Q2 24 | 11.0% | 17.8% | ||
| Q1 24 | 7.6% | 8.6% |
资本支出强度CTKBRMAX
| Q4 25 | 1.6% | 10.4% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 3.5% | 2.2% | ||
| Q1 25 | 2.0% | 2.3% | ||
| Q4 24 | 1.6% | 9.1% | ||
| Q3 24 | 2.0% | 1.7% | ||
| Q2 24 | 2.3% | 2.4% | ||
| Q1 24 | 1.3% | 3.3% |
现金转化率CTKBRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 10.28× | ||
| Q3 24 | 14.05× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
